Integrated pharmacological and structural profiling reveals CB1 residue interaction patterns associated with synthetic cannabinoid receptor agonist efficacy
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background and Purpose
Among new psychoactive substances, synthetic cannabinoid receptor agonists (SCRAs) encompass considerable structural diversity and show wide variation in cannabinoid receptor 1 (CB1) potency and efficacy, but the molecular and receptor-interaction characteristics underlying these differences remain unclear. We assessed the pharmacological profiles of 16 SCRAs and examined structural features associated with differences in CB1 potency and efficacy.
Experimental Approach
CB1 agonist activity was measured in a CB1-Ga15-based Ca 2+ assay, and cataleptic effects were assessed in mice. Ligand-receptor interactions were characterized by molecular docking to an active-state CB1 structure. Principal component analysis (PCA) was applied to residue-level interaction profiles, and the resulting scores were tested for associations with CB1 potency and efficacy.
Key Results
Potency and efficacy varied widely across cellular and animal assays, with several SCRAs exhibiting different pharmacological responses across the two experimental systems. PCA identified an interaction pattern whose PC1 scores were significantly associated with E max but not EC 50 , with contributions from activation-related CB1 residues including the PHE200-TRP356 toggle switch. Molecular descriptor analysis likewise identified structural features significantly associated with in vitro and in vivo E max .
Conclusion and Implications
Our findings suggest that CB1 efficacy is associated with distinct receptor-interaction patterns among structurally diverse SCRAs. Combining functional pharmacology with receptor-level interaction analysis provides structural insight into SCRA efficacy and may help prioritize emerging compounds for further pharmacological and behavioral evaluation.
Bullet Point Summary
What is already known
-
SCRAs act at CB1 receptors and vary widely in potency and efficacy.
-
Structurally similar SCRAs can produce markedly different pharmacological effects.
What this study adds
-
PC1 derived from residue-interaction profiles was significantly associated with in vitro E max in 11 SCRAs.
-
Selected molecular descriptors and PC1 were associated with E max , but not EC 50 .
Clinical significance
-
Efficacy-linked interaction patterns may help prioritize emerging SCRAs for pharmacological and behavioral evaluation.
